JP2008509147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509147A5 JP2008509147A5 JP2007524968A JP2007524968A JP2008509147A5 JP 2008509147 A5 JP2008509147 A5 JP 2008509147A5 JP 2007524968 A JP2007524968 A JP 2007524968A JP 2007524968 A JP2007524968 A JP 2007524968A JP 2008509147 A5 JP2008509147 A5 JP 2008509147A5
- Authority
- JP
- Japan
- Prior art keywords
- desmethylclozapine
- use according
- clozapine
- medicament
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 claims 25
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 18
- 229960004170 clozapine Drugs 0.000 claims 17
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 8
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 8
- 230000008484 agonism Effects 0.000 claims 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 6
- 208000028017 Psychotic disease Diseases 0.000 claims 5
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- -1 etraphone Chemical compound 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 3
- OHFQSNUBVNIZRV-UHFFFAOYSA-N 1-(4-phenylbutyl)piperazine Chemical compound C1CNCCN1CCCCC1=CC=CC=C1 OHFQSNUBVNIZRV-UHFFFAOYSA-N 0.000 claims 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229940003380 geodon Drugs 0.000 claims 2
- 229940095895 haldol Drugs 0.000 claims 2
- 229910003002 lithium salt Inorganic materials 0.000 claims 2
- 159000000002 lithium salts Chemical class 0.000 claims 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- 229950000688 phenothiazine Drugs 0.000 claims 2
- 229960004431 quetiapine Drugs 0.000 claims 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 2
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims 2
- 229940035004 seroquel Drugs 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 chlorpromazine Drugs 0.000 claims 1
- 229940068796 clozaril Drugs 0.000 claims 1
- 229940088505 compazine Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229960000394 droperidol Drugs 0.000 claims 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical group [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 229960000423 loxapine Drugs 0.000 claims 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 1
- 229960000300 mesoridazine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims 1
- 229960003634 pimozide Drugs 0.000 claims 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims 1
- 229960003111 prochlorperazine Drugs 0.000 claims 1
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 239000003723 serotonin 1A agonist Substances 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 229960002784 thioridazine Drugs 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/913,117 US20050085463A1 (en) | 2003-01-23 | 2004-08-05 | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US61755304P | 2004-10-08 | 2004-10-08 | |
| US11/098,892 US20050250767A1 (en) | 2003-01-23 | 2005-04-04 | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| PCT/US2005/027645 WO2006017614A1 (en) | 2004-08-05 | 2005-08-04 | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509147A JP2008509147A (ja) | 2008-03-27 |
| JP2008509147A5 true JP2008509147A5 (enExample) | 2008-10-02 |
Family
ID=35511003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524968A Pending JP2008509147A (ja) | 2004-08-05 | 2005-08-04 | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1778244A1 (enExample) |
| JP (1) | JP2008509147A (enExample) |
| AU (1) | AU2005271513A1 (enExample) |
| CA (1) | CA2576153A1 (enExample) |
| WO (1) | WO2006017614A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2550735A1 (en) | 2003-12-22 | 2005-07-14 | Acadia Pharmaceuticals Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| CA2649917A1 (en) * | 2006-05-04 | 2007-11-15 | Solvay Pharmaceuticals B.V. | Muscarinic agonists to treat impulse control disorders |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| GB0701970D0 (en) | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| GB0708186D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| CN106749219A (zh) * | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
| US20060233843A1 (en) * | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
-
2005
- 2005-08-04 AU AU2005271513A patent/AU2005271513A1/en not_active Abandoned
- 2005-08-04 WO PCT/US2005/027645 patent/WO2006017614A1/en not_active Ceased
- 2005-08-04 JP JP2007524968A patent/JP2008509147A/ja active Pending
- 2005-08-04 EP EP05802835A patent/EP1778244A1/en not_active Withdrawn
- 2005-08-04 CA CA002576153A patent/CA2576153A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8138169B2 (en) | Combination therapy for bipolar disorder | |
| JP2006515628A5 (enExample) | ||
| JP5241228B2 (ja) | 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠 | |
| RU2005126614A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
| US20060039866A1 (en) | Method for treating sleep-related breathing disorders | |
| US20090281078A1 (en) | Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders | |
| TWI426906B (zh) | 治療精神分裂症的醫藥組成物 | |
| JP2010530422A (ja) | うつ病のための組合せ治療 | |
| JP2006528676A (ja) | 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ | |
| JP2009525343A5 (enExample) | ||
| CN105431144A (zh) | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 | |
| RS53491B1 (sr) | Kompozicije za lečenje centralno posredovane mučnine i povraćanja | |
| JP2016520653A5 (enExample) | ||
| JP2010513229A (ja) | 軽減された肝毒性を含む最小限に抑制された副作用を有するアセトアミノフェン組成物 | |
| RU2011146032A (ru) | Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности | |
| Leo et al. | Atypical antipsychotic use in the treatment of psychosis in primary care | |
| JP2008509147A5 (enExample) | ||
| CN117177741A (zh) | 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合 | |
| US20090035370A1 (en) | Dosage form and method of use | |
| US20220370454A1 (en) | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics | |
| EP4091607A1 (en) | Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics | |
| CN101123963A (zh) | 沙可美林单独或与情绪稳定剂或抗躁狂剂组合治疗双相情感障碍 | |
| WO2016027259A1 (en) | Cns pharmaceutical compositions and methods of use | |
| WO2008069726A1 (en) | Treatment of resistant schizophrenia and other cns disorders by the use of thioxanthenes | |
| CN1681512B (zh) | 2,3-苯并二氮杂草在制备治疗与基底神经节相关的运动疾病的药物中的应用 |